Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 11:33 PM
Ignite Modification Date: 2025-12-24 @ 11:33 PM
NCT ID: NCT02771756
Eligibility Criteria: Inclusion Criteria: * Patients aged between 18 and 70 years old * Breast or lung cancer was diagnosed by pathology or cytology * ECOG score: 0-2 points * PG-SGA: 2-8 points, while the weight loss within 3 months less than 5% * The organ function is good, with chemotherapy index. ANC is equal to or over 1.5 \* 10\^9/L, PLT is equal to or over 100\* 10\^9/L, HGB is equal to or over 90g/L * Bilirubin is equal to or less than 1.5 times of the normal upper limit, AP, AST, ALT is less than or equal to 2 times of normal upper limit * Ccr is equal to or over 50mL/min * Life expectancy is equal to or over 12 weeks Exclusion Criteria: * Complete or incomplete intestinal obstruction * A severe infection or difficult to control diabetes * History of organ transplantation, or current use of immunosuppressive agents * An intervention in nutritional supplements, or a metabolic disorder * Parenteral nutrition must be applied * Alcoholism or drug addiction * Pregnancy or lactation, or women of childbearing age refuse contraception * There are potential factors that interfere with the mental, psychological, family, social or geographical and other factors of the research project * There are other diseases that may interfere with the results of this study, such as the second primary tumor * For any other reason, the researchers were unable to complete the study
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 70 Years
Study: NCT02771756
Study Brief:
Protocol Section: NCT02771756